168 related articles for article (PubMed ID: 37932205)
61. Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor.
Yukihiro K; Teishima J; Goto K; Aoki G; Sekino Y; Hayashi T; Hasegawa Y; Mita K; Kato M; Kajiwara M; Shigeta M; Maruyama S; Kadonishi Y; Fujiwara S; Hinata N
Urol Oncol; 2022 Oct; 40(10):455.e11-455.e18. PubMed ID: 35851184
[TBL] [Abstract][Full Text] [Related]
62. Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma.
Ishihara H; Nishimura K; Ikeda T; Fukuda H; Yoshida K; Iizuka J; Kondo T; Takagi T
Urol Oncol; 2024 Sep; 42(9):291.e27-291.e37. PubMed ID: 38653590
[TBL] [Abstract][Full Text] [Related]
63. Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy.
Riveros C; Ranganathan S; Xu J; Chang C; Kaushik D; Morgan M; Miles BJ; Muhammad T; Anis M; Aghazadeh M; Zhang J; Efstathiou E; Klaassen Z; Brooks MA; Rini B; Wallis CJD; Satkunasivam R
Urol Oncol; 2023 Mar; 41(3):150.e1-150.e9. PubMed ID: 36610815
[TBL] [Abstract][Full Text] [Related]
64. Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.
Mahoney KM; Jacobus S; Bhatt RS; Song J; Carvo I; Cheng SC; Simpson M; Fay AP; Puzanov I; Michaelson MD; Atkins MB; McDermott DF; Signoretti S; Choueiri TK
Clin Genitourin Cancer; 2016 Aug; 14(4):304-313.e6. PubMed ID: 27036973
[TBL] [Abstract][Full Text] [Related]
65. Effect of Annexin A2 on prognosis and sensitivity to immune checkpoint plus tyrosine kinase inhibition in metastatic renal cell carcinoma.
Wang J; Lin J; Wang J; Wang Y; Zhu Y; Xu X; Guo J
Discov Oncol; 2024 Mar; 15(1):86. PubMed ID: 38519766
[TBL] [Abstract][Full Text] [Related]
66. A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study).
Grünwald V; Hilser T; Meiler J; Goebell PJ; Ivanyi P; Strauss A; Hartmann A; Bedke J; Bergmann L
Oncol Res Treat; 2022; 45(5):272-280. PubMed ID: 35045416
[TBL] [Abstract][Full Text] [Related]
67. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.
Graham J; Wells JC; Dudani S; Gan CL; Donskov F; Lee JL; Kollmannsberger CK; Meza L; Beuselinck B; Hansen A; North SA; Bjarnason GA; Sayegh N; Kanesvaran R; Wood LA; Hotte SJ; McKay RR; Choueiri TK; Heng DYC
Eur J Cancer; 2022 Aug; 171():124-132. PubMed ID: 35717820
[TBL] [Abstract][Full Text] [Related]
68. Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy: Older patients more prone to toxicity.
Hermansen CK; Donskov F
J Geriatr Oncol; 2021 Jun; 12(5):827-833. PubMed ID: 33388280
[TBL] [Abstract][Full Text] [Related]
69. Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma.
Poprach A; Kiss I; Stanik M; Barusova T; Pospisilova L; Fiala O; Kopecky J; Richter I; Melichar B; Studentova H; Lakomy R; Holanek M; Rozsypalova A; Zemanková A; Svoboda M; Buchler T
Target Oncol; 2023 Nov; 18(6):893-903. PubMed ID: 37957520
[TBL] [Abstract][Full Text] [Related]
70. Comparison of Tyrosine Kinase Inhibitor
Miyake H; Imai S; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
Anticancer Res; 2017 Mar; 37(3):1523-1528. PubMed ID: 28314328
[TBL] [Abstract][Full Text] [Related]
71. Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Wells JC; Graham J; Beuselinck B; Bjarnason GA; Donskov F; Hansen AR; McKay RR; Vaishampayan U; De Velasco G; Duh MS; Huynh L; Nguyen C; Zanotti G; Ramaswamy K; Choueiri TK; Heng DYC
Clin Genitourin Cancer; 2020 Aug; 18(4):e350-e359. PubMed ID: 31926879
[TBL] [Abstract][Full Text] [Related]
72. Real-world outcomes among patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first-line setting.
Apple J; Shenolikar R; De Silva K; Sun P; Spira A
Cancer Med; 2023 Jun; 12(12):13415-13425. PubMed ID: 37306623
[TBL] [Abstract][Full Text] [Related]
73. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
Wiele AJ; Bathala TK; Hahn AW; Xiao L; Duran M; Ross JA; Jonasch E; Shah AY; Campbell MT; Msaouel P; Tannir NM
Oncologist; 2021 Jun; 26(6):476-482. PubMed ID: 33792094
[TBL] [Abstract][Full Text] [Related]
74. Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials.
Manneh R; Lema M; Carril-Ajuria L; Ibatá L; Martínez S; Castellano D; de Velasco G
Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327380
[TBL] [Abstract][Full Text] [Related]
75. Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma.
Chehrazi-Raffle A; Meza L; Alcantara M; Dizman N; Bergerot P; Salgia N; Hsu J; Ruel N; Salgia S; Malhotra J; Karczewska E; Kortylewski M; Pal S
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688021
[TBL] [Abstract][Full Text] [Related]
76. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
[TBL] [Abstract][Full Text] [Related]
77. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
78. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
[TBL] [Abstract][Full Text] [Related]
79. The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.
Janisch F; Hillemacher T; Fuehner C; D'Andrea D; Meyer CP; Klotzbücher T; Kienapfel C; Vetterlein MW; Kimura S; Abufaraj M; Dahlem R; Shariat SF; Fisch M; Rink M
Urol Oncol; 2020 Sep; 38(9):739.e9-739.e15. PubMed ID: 32576526
[TBL] [Abstract][Full Text] [Related]
80. Baseline and Dynamic Changes in Hemoglobin Levels Predict Treatment Response and Prognosis in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study.
Yang YH; Ansel S; Meerveld-Eggink A; Jackson-Spence F; Rallis K; Brian P; Choy J; Sng C; Adeniran P; Amin J; Galope S; Anderson N; Bex A; Powles T; Venugopal B; Szabados B
Clin Genitourin Cancer; 2023 Aug; 21(4):e242-e251. PubMed ID: 36922286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
